CEO Discusses Recent Stem Cell Breakthrough, Submission of Proposal to Department of Defense and Progress of Phase II Cancer Trial in Interview CLEVELAND, April 27 /PRNewswire-FirstCall/...
Date Change to June 12 CLEVELAND, April 4 /PRNewswire-FirstCall/ -- Cleveland BioLabs, Inc. (NASDAQ:CBLI)(BSE:CFB), today announced that the Company will hold its 2007 annual stockholders...
CLEVELAND, March 26 /PRNewswire-FirstCall/ -- Cleveland BioLabs, Inc. (NASDAQ:CBLI)(BSE:CFB), today announced that the Company is scheduled to present at the ValueRich Small-Cap Financial Expo...
Company plans to submit Protectan CBLB502 for Department of Defense request for proposal for medical radiation countermeasures to treat gastrointestinal effects of acute radiation syndrome...
CLEVELAND, Feb. 8 /PRNewswire-FirstCall/ -- Cleveland BioLabs, Inc. (NASDAQ:CBLI)(BSE:CFB), today announced that the Company is scheduled to present at the Roth Capital Partners 19th Annual OC...
CLEVELAND, Feb. 6 /PRNewswire-FirstCall/ -- Cleveland BioLabs, Inc. (NASDAQ:CBLI)(BSE:CFB), today announced that the Company is scheduled to present at the BIO CEO and Investor Conference to be...
CLEVELAND, Feb. 5 /PRNewswire-FirstCall/ -- Cleveland BioLabs, Inc. (NASDAQ:CBLI)(BSE:CFB), today announced that the Company was featured in an article in the February 5, 2007, issue of...
CLEVELAND, Jan. 23 /PRNewswire-FirstCall/ -- Cleveland BioLabs, Inc. (NASDAQ:CBLI) (BSE:CFB), today announced that Chief Scientist Andrei Gudkov, Ph.D., D. Sci., was interviewed by...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.